Enrique Conterno, via Eli Lilly
As questions swirl around lead drug, FibroGen (and AstraZeneca) find a new champion from Big Pharma
Two months after Enrique Conterno left his high-profile post as the head of Lilly Diabetes and Lilly USA, the 27-year pharma vet is back in the game — this time as the newly appointed CEO of a closely-watched biotech.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
